|
시장보고서
상품코드
1886396
혈관 육종 치료 시장 : 세계 산업 규모, 점유율, 동향, 기회 및 예측 - 유형별, 치료법별, 최종사용자별, 지역별, 경쟁별 세분화(2020-2030년)Angiosarcoma Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Treatment, By End user, By Region and Competition, 2020-2030F |
||||||
세계의 혈관 육종 치료 시장은 2024년에 2억 8,011만 달러로 평가되며, 2030년까지 CAGR 6.11%로 성장하며, 3억 9,985만 달러에 달할 것으로 예측됩니다. 혈관육종 치료에는 수술, 방사선 치료, 화학요법, 표적 약물요법 등 다양한 치료 전략이 포함되며, 공격성이 높고 희귀한 이 암을 관리하기 위해 다양한 의료 현장에서 사용되고 있습니다. 시장 확대는 기본적으로 전 세계에서 혈관육종 사례가 증가함에 따라 첨단 치료적 개입이 필요한 혈관육종 환자 증가에 의해 주도되고 있습니다.
| 시장 개요 | |
|---|---|
| 예측 기간 | 2026-2030년 |
| 시장 규모 : 2024년 | 2억 8,011만 달러 |
| 시장 규모 : 2030년 | 3억 9,985만 달러 |
| CAGR : 2025-2030년 | 6.11% |
| 가장 빠르게 성장하는 부문 | 면역치료 |
| 최대 시장 | 북미 |
주요 시장 성장 촉진요인
세계 혈관육종 치료 시장은 혈관육종 발생률 증가로 인해 큰 영향을 받고 있습니다. 이 공격성이 강한 희귀암은 발생률이 눈에 띄게 증가하고 있는 것으로 확인되어 치료적 개입을 필요로 하는 환자 수가 확대되고 있습니다.
주요 시장 과제
세계 혈관육종 치료 시장 확대에 있으며, 가장 큰 장벽은 표준화된 치료 프로토콜의 지속적인 부족입니다. 혈관육종의 고유한 희귀성과 불균일한 특성으로 인해 보편적으로 받아들여지는 임상 가이드라인이 부족하고, 그 결과 의료기관마다 환자 치료에 상당한 편차가 발생하고 있습니다.
주요 시장 동향
면역치료의 적용 확대는 환자의 면역체계를 암 치료에 활용한다는 점에서 전 세계 혈관육종 치료 시장에서 중요한 동향입니다. 이 접근법은 혈관육종과 같은 침습성 희귀암과 같이 기존 치료법이 효과가 제한적인 희귀암에서 매우 중요합니다.
자주 묻는 질문
목차
제1장 개요
제2장 조사 방법
제3장 개요
제4장 고객의 소리
제5장 세계의 혈관 육종 치료 시장 전망
- 시장 규모·예측
- 금액별
- 시장 점유율·예측
- 유형별(혈관 육종, 림프관 육종, 실질성 혈관 육종)
- 치료법별(외과수술, 방사선 요법, 화학요법, 표적치료, 면역치료, 기타)
- 최종사용자별(병원·진료소, 외래 수술 센터, 온라인 약국)
- 지역별
- 기업별(2024)
- 시장 맵
제6장 북미의 혈관 육종 치료 시장 전망
- 시장 규모·예측
- 시장 점유율·예측
- 북미 : 국가별 분석
- 미국
- 캐나다
- 멕시코
제7장 유럽의 혈관 육종 치료 시장 전망
- 시장 규모·예측
- 시장 점유율·예측
- 유럽 : 국가별 분석
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
제8장 아시아태평양의 혈관 육종 치료 시장 전망
- 시장 규모·예측
- 시장 점유율·예측
- 아시아태평양 : 국가별 분석
- 중국
- 인도
- 일본
- 한국
- 호주
제9장 중동 및 아프리카의 혈관 육종 치료 시장 전망
- 시장 규모·예측
- 시장 점유율·예측
- 중동 및 아프리카 : 국가별 분석
- 사우디아라비아
- 아랍에미리트
- 남아프리카공화국
제10장 남미의 혈관 육종 치료 시장 전망
- 시장 규모·예측
- 시장 점유율·예측
- 남미 : 국가별 분석
- 브라질
- 콜롬비아
- 아르헨티나
제11장 시장 역학
- 촉진요인
- 과제
제12장 시장 동향과 발전
- 합병·인수
- 제품 출시
- 최근 동향
제13장 세계의 혈관 육종 치료 시장 : SWOT 분석
제14장 Porter's Five Forces 분석
- 업계내 경쟁
- 신규 참여의 가능성
- 공급업체의 힘
- 고객의 힘
- 대체품의 위협
제15장 경쟁 구도
- Novartis AG
- Bayer AG
- Sanofi AG
- Amgen Inc
- Eli Lilly and Company
- Genentech Inc.
- Janssen Pharmaceuticals
- AbbVie Inc
- Bausch Health Companies Inc.
- GlaxoSmithKline Plc
제16장 전략적 제안
제17장 조사회사 소개·면책사항
KSAThe Global Angiosarcoma Treatment Market , valued at USD 280.11 Million in 2024, is projected to experience a CAGR of 6.11% to reach USD 399.85 Million by 2030. Angiosarcoma treatment encompasses a range of therapeutic strategies, including surgery, radiation therapy, chemotherapy, and targeted drug therapies, employed across various healthcare settings to manage this aggressive and rare cancer. The market's expansion is fundamentally driven by the increasing incidence of angiosarcoma cases globally, necessitating advanced therapeutic interventions.
| Market Overview | |
|---|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 280.11 Million |
| Market Size 2030 | USD 399.85 Million |
| CAGR 2025-2030 | 6.11% |
| Fastest Growing Segment | Immunotherapy |
| Largest Market | North America |
Key Market Drivers
The global angiosarcoma treatment market is significantly influenced by the rising incidence of angiosarcoma cases. This aggressive rare cancer has demonstrated a notable increase in its occurrence, thereby expanding the patient population requiring therapeutic intervention. According to a study published in JAMA Network Open in April 2024, the U. S. incidence of angiosarcoma doubled from 657 newly diagnosed cases in 2001 to 1312 cases in 2019.
Key Market Challenges
A significant impediment to the expansion of the Global Angiosarcoma Treatment Market is the persistent lack of standardized treatment protocols. The inherent rarity and heterogeneous nature of angiosarcoma contribute to an absence of universally accepted clinical guidelines, resulting in considerable variability in patient care across institutions. This inconsistency directly hampers the development and adoption of advanced therapeutic interventions.
Key Market Trends
The expanding application of immunotherapy is a significant trend in the global angiosarcoma treatment market, leveraging the patient's immune system against cancer. This approach is vital for aggressive, rare cancers like angiosarcoma, where traditional therapies often have limited success. Research into tumor immunology has advanced, leading to innovative immune checkpoint inhibitors.
Key Market Players
- Novartis AG
- Bayer AG
- Sanofi AG
- Amgen Inc
- Eli Lilly and Company
- Genentech Inc.
- Janssen Pharmaceuticals
- AbbVie Inc
- Bausch Health Companies Inc.
- GlaxoSmithKline Plc
Report Scope:
In this report, the Global Angiosarcoma Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Angiosarcoma Treatment Market , By Type:
- Hemangiosarcoma
- Lymphangiosarcoma
- Parenchymal Angiosarcoma
Angiosarcoma Treatment Market , By Treatment:
- Surgery
- Radiotherapy
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Others
Angiosarcoma Treatment Market , By End user:
- Hospital & Clinics
- Ambulatory Surgical Centers
- Online Pharmacies
Angiosarcoma Treatment Market , By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the Global Angiosarcoma Treatment Market .
Available Customizations:
Global Angiosarcoma Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Angiosarcoma Treatment Market Outlook
- 5.1. Market Size & Forecast
- 5.1.1. By Value
- 5.2. Market Share & Forecast
- 5.2.1. By Type (Hemangiosarcoma, Lymphangiosarcoma, Parenchymal Angiosarcoma)
- 5.2.2. By Treatment (Surgery, Radiotherapy, Chemotherapy, Targeted Therapy, Immunotherapy, Others)
- 5.2.3. By End user (Hospital & Clinics, Ambulatory Surgical Centers, Online Pharmacies)
- 5.2.4. By Region
- 5.2.5. By Company (2024)
- 5.3. Market Map
6. North America Angiosarcoma Treatment Market Outlook
- 6.1. Market Size & Forecast
- 6.1.1. By Value
- 6.2. Market Share & Forecast
- 6.2.1. By Type
- 6.2.2. By Treatment
- 6.2.3. By End user
- 6.2.4. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States Angiosarcoma Treatment Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.1.1. By Value
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Type
- 6.3.1.2.2. By Treatment
- 6.3.1.2.3. By End user
- 6.3.1.1. Market Size & Forecast
- 6.3.2. Canada Angiosarcoma Treatment Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.1.1. By Value
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Type
- 6.3.2.2.2. By Treatment
- 6.3.2.2.3. By End user
- 6.3.2.1. Market Size & Forecast
- 6.3.3. Mexico Angiosarcoma Treatment Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.1.1. By Value
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Type
- 6.3.3.2.2. By Treatment
- 6.3.3.2.3. By End user
- 6.3.3.1. Market Size & Forecast
- 6.3.1. United States Angiosarcoma Treatment Market Outlook
7. Europe Angiosarcoma Treatment Market Outlook
- 7.1. Market Size & Forecast
- 7.1.1. By Value
- 7.2. Market Share & Forecast
- 7.2.1. By Type
- 7.2.2. By Treatment
- 7.2.3. By End user
- 7.2.4. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. Germany Angiosarcoma Treatment Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.1.1. By Value
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Type
- 7.3.1.2.2. By Treatment
- 7.3.1.2.3. By End user
- 7.3.1.1. Market Size & Forecast
- 7.3.2. France Angiosarcoma Treatment Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.1.1. By Value
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Type
- 7.3.2.2.2. By Treatment
- 7.3.2.2.3. By End user
- 7.3.2.1. Market Size & Forecast
- 7.3.3. United Kingdom Angiosarcoma Treatment Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.1.1. By Value
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Type
- 7.3.3.2.2. By Treatment
- 7.3.3.2.3. By End user
- 7.3.3.1. Market Size & Forecast
- 7.3.4. Italy Angiosarcoma Treatment Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.1.1. By Value
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Type
- 7.3.4.2.2. By Treatment
- 7.3.4.2.3. By End user
- 7.3.4.1. Market Size & Forecast
- 7.3.5. Spain Angiosarcoma Treatment Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.1.1. By Value
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Type
- 7.3.5.2.2. By Treatment
- 7.3.5.2.3. By End user
- 7.3.5.1. Market Size & Forecast
- 7.3.1. Germany Angiosarcoma Treatment Market Outlook
8. Asia Pacific Angiosarcoma Treatment Market Outlook
- 8.1. Market Size & Forecast
- 8.1.1. By Value
- 8.2. Market Share & Forecast
- 8.2.1. By Type
- 8.2.2. By Treatment
- 8.2.3. By End user
- 8.2.4. By Country
- 8.3. Asia Pacific: Country Analysis
- 8.3.1. China Angiosarcoma Treatment Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.1.1. By Value
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Type
- 8.3.1.2.2. By Treatment
- 8.3.1.2.3. By End user
- 8.3.1.1. Market Size & Forecast
- 8.3.2. India Angiosarcoma Treatment Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.1.1. By Value
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Type
- 8.3.2.2.2. By Treatment
- 8.3.2.2.3. By End user
- 8.3.2.1. Market Size & Forecast
- 8.3.3. Japan Angiosarcoma Treatment Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.1.1. By Value
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Type
- 8.3.3.2.2. By Treatment
- 8.3.3.2.3. By End user
- 8.3.3.1. Market Size & Forecast
- 8.3.4. South Korea Angiosarcoma Treatment Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.1.1. By Value
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Type
- 8.3.4.2.2. By Treatment
- 8.3.4.2.3. By End user
- 8.3.4.1. Market Size & Forecast
- 8.3.5. Australia Angiosarcoma Treatment Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.1.1. By Value
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Type
- 8.3.5.2.2. By Treatment
- 8.3.5.2.3. By End user
- 8.3.5.1. Market Size & Forecast
- 8.3.1. China Angiosarcoma Treatment Market Outlook
9. Middle East & Africa Angiosarcoma Treatment Market Outlook
- 9.1. Market Size & Forecast
- 9.1.1. By Value
- 9.2. Market Share & Forecast
- 9.2.1. By Type
- 9.2.2. By Treatment
- 9.2.3. By End user
- 9.2.4. By Country
- 9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Angiosarcoma Treatment Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.1.1. By Value
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Type
- 9.3.1.2.2. By Treatment
- 9.3.1.2.3. By End user
- 9.3.1.1. Market Size & Forecast
- 9.3.2. UAE Angiosarcoma Treatment Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.1.1. By Value
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Type
- 9.3.2.2.2. By Treatment
- 9.3.2.2.3. By End user
- 9.3.2.1. Market Size & Forecast
- 9.3.3. South Africa Angiosarcoma Treatment Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.1.1. By Value
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Type
- 9.3.3.2.2. By Treatment
- 9.3.3.2.3. By End user
- 9.3.3.1. Market Size & Forecast
- 9.3.1. Saudi Arabia Angiosarcoma Treatment Market Outlook
10. South America Angiosarcoma Treatment Market Outlook
- 10.1. Market Size & Forecast
- 10.1.1. By Value
- 10.2. Market Share & Forecast
- 10.2.1. By Type
- 10.2.2. By Treatment
- 10.2.3. By End user
- 10.2.4. By Country
- 10.3. South America: Country Analysis
- 10.3.1. Brazil Angiosarcoma Treatment Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.1.1. By Value
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Type
- 10.3.1.2.2. By Treatment
- 10.3.1.2.3. By End user
- 10.3.1.1. Market Size & Forecast
- 10.3.2. Colombia Angiosarcoma Treatment Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.1.1. By Value
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Type
- 10.3.2.2.2. By Treatment
- 10.3.2.2.3. By End user
- 10.3.2.1. Market Size & Forecast
- 10.3.3. Argentina Angiosarcoma Treatment Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.1.1. By Value
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Type
- 10.3.3.2.2. By Treatment
- 10.3.3.2.3. By End user
- 10.3.3.1. Market Size & Forecast
- 10.3.1. Brazil Angiosarcoma Treatment Market Outlook
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Merger & Acquisition (If Any)
- 12.2. Product Launches (If Any)
- 12.3. Recent Developments
13. Global Angiosarcoma Treatment Market : SWOT Analysis
14. Porter's Five Forces Analysis
- 14.1. Competition in the Industry
- 14.2. Potential of New Entrants
- 14.3. Power of Suppliers
- 14.4. Power of Customers
- 14.5. Threat of Substitute Products
15. Competitive Landscape
- 15.1. Novartis AG
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
- 15.2. Bayer AG
- 15.3. Sanofi AG
- 15.4. Amgen Inc
- 15.5. Eli Lilly and Company
- 15.6. Genentech Inc.
- 15.7. Janssen Pharmaceuticals
- 15.8. AbbVie Inc
- 15.9. Bausch Health Companies Inc.
- 15.10. GlaxoSmithKline Plc
